CD73 Antibody-Drug Conjugate Targeting Tumor Immune Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors with abnormal CD73 expression face challenges due to CD73's role in promoting tumor immune escape, growth, metastasis, and drug resistance, with a lack of specific antibody-drug conjugates targeting human CD73 in clinical practice.
Innovation Solution
Development of antibodies targeting human CD73 that inhibit its catalytic activity, specifically blocking the hydrolysis of adenosine monophosphate to adenosine, and their use in antibody-drug conjugates to enhance anti-tumor therapy efficacy while reducing resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD73 is used as a target for tumor treatment, then anti-tumor efficacy is improved, but drug resistance develops
Solution Approach 1:
The patent combines a CD73-targeting antibody with a cytotoxic drug through a linker to create an antibody-drug conjugate (ADC). This merging of the targeting component (antibody) and the therapeutic component (drug) allows for precise delivery of the cytotoxic agent to CD73-expressing tumor cells, thereby improving anti-tumor efficacy while reducing systemic toxicity and overcoming drug resistance mechanisms.
Solution Approach 2:
The antibody serves as an intermediary that specifically binds to CD73 on tumor cells, mediating the delivery of the cytotoxic drug to the target. This intermediary approach ensures that the drug is delivered selectively to tumor cells expressing CD73, enhancing therapeutic efficacy while minimizing off-target effects that could lead to resistance.
2Productivity
If conventional chemotherapy is used, then tumor growth is inhibited, but immune escape is promoted
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (CD73 enzyme) responsible for generating the immunosuppressive microenvironment. By specifically inhibiting CD73 with the antibody-drug conjugate, the harmful adenosine production pathway is blocked without the broad, non-specific toxicity of conventional chemotherapy, thereby inhibiting tumor growth while preventing immune escape.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific cytotoxicity (conventional chemotherapy) to specific target-mediated cytotoxicity (ADC). This parameter change involves targeting the enzymatic activity of CD73, which is overexpressed in tumor cells and responsible for immunosuppression, thereby achieving tumor growth inhibition while reversing the immunosuppressive microenvironment.
3Speed
If CD73 expression is high, then tumor progression is accelerated, but treatment response is poor
Solution Approach 1:
The antibody component of the ADC performs preliminary action by binding to CD73 on the tumor cell surface before the cytotoxic drug is released. This preliminary binding ensures that the drug is delivered only to cells with high CD73 expression, which are the cells driving tumor progression. The antibody's presence on the cell surface triggers internalization and subsequent drug release, creating a targeted therapeutic effect that is proportional to CD73 expression levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit tumor growth and metastasis, improve anti-tumor immune responses, and reduce drug resistance, offering a new therapeutic approach for tumors with abnormal CD73 expression.
Implementation Method 1
an antibody targeting human CD73, which has the activity of blocking CD73 from catalyzing the hydrolysis of adenosine monophosphate (AMP) into adenosine
Implementation Method 2
CD73 is an extracellular 5-nuclease (NT5E) with a molecular weight of 70 KD... Extracellular ATP/ADP is hydrolyzed by CD39 to produce adenosine monophosphate (AMP)... The AMP produced by a series of metabolism is catalyzed by CD73 to remove phosphate groups, thereby producing a large amount of adenosines (ADOs)
Data Source
AI summary
Disclosed by the present invention are a targeted CD73 antibody and an antibody-drug conjugate (ADC), and a preparation method therefor and application thereof. Further disclosed is a method for preparing the described monoclonal antibody and ADC. The monoclonal antibody and the corresponding ADC disclosed by the present invention can be efficiently and highly specifically combined with purified CD73 protein and CD73 on the surfaces of multiple tumor cells to block the catalytic activity of CD73 enzyme, and have high affinity, low immunogenicity and significant anti-tumor effect.